Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia

被引:25
作者
Wang, Chang-Zheng [1 ]
Hu, Shun-Lin [1 ]
Wang, Lin [1 ]
Li, Min [1 ]
Li, Huan-Tian [2 ]
机构
[1] Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Gastroenterol, Xiangyang, Hubei, Peoples R China
[2] Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Gen Surg, Xiangyang 441000, Hubei, Peoples R China
关键词
chest CT; clinical features; COVID-19; risk factors; SARS-CoV-2; LOPINAVIR/RITONAVIR;
D O I
10.1002/jmv.26071
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The purpose of this study was to investigate the early risk factors for the exacerbation of coronavirus disease 2019 (COVID-19) pneumonia. Restrospective analysis of clinical data of 85 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including gender, age, comorbidities, symptoms, blood routine, clotting profile, biochemical examination, albumin, myocardial enzyme profile, inflammatory markers, and chest computed tomography (CT). All laboratory examinations were measured within first 24 hours after admission, and chest CT was performed before admission. A total of 56 (65.9%) patients had a history of exposure to the Huanan seafood market in Wuhan. Fever and dry cough accounted for the highest percentage of all symptoms. Male COVID-2019 patients were more likely to develop severe pneumonia. Patients with severe and critical conditions are older and have higher rates of hypertension (P = .003) and coronary heart disease (P = .017). All severe and critical patients infected with SARS-CoV-2 showed bilateral lung involvement and have more multiple lobes involvement than common patients (P < .001). Severe and critical patients showed higher white blood cell count (P = .006), neutrophil (NEU) count (P = .001), NEU% (P = .002), procalcitonin (P = .011), C-reactive protein (P = .003), prothrombin time (P = .035), D-dimer (P = .025), aspartate aminotransferase (P = .006), and lower lymphocyte (LYM) count (P = .019), LYM% (P = .001), albumin (P < .001). Logistic regression analysis showed that NEU count is an independent risk factor for deterioration, with the threshold of 6.5 x 10(9)center dot L-1. We concluded that the laboratory independent risk factor for the progression of COVID-19 pneumonia is NEU count. In addition, COVID-19 patients with bilateral lung involvement or multiple lobes involvement should be taken seriously and actively treated to prevent deterioration of the disease.
引用
收藏
页码:2593 / 2599
页数:7
相关论文
共 14 条
[1]   Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [J].
Agostini, Maria L. ;
Andres, Erica L. ;
Sims, Amy C. ;
Graham, Rachel L. ;
Sheahan, Timothy P. ;
Lu, Xiaotao ;
Smith, Everett Clinton ;
Case, James Brett ;
Feng, Joy Y. ;
Jordan, Robert ;
Ray, Adrian S. ;
Cihlar, Tomas ;
Siegel, Dustin ;
Mackman, Richard L. ;
Clarke, Michael O. ;
Baric, Ralph S. ;
Denison, Mark R. .
MBIO, 2018, 9 (02)
[2]   Convalescent plasma as a potential therapy for COVID-19 [J].
Chen, Long ;
Xiong, Jing ;
Bao, Lei ;
Shi, Yuan .
LANCET INFECTIOUS DISEASES, 2020, 20 (04) :398-400
[3]  
Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203
[4]   Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study [J].
Hicks, C ;
King, MS ;
Gulick, RA ;
White, AC ;
Eron, JJ ;
Kessler, HA ;
Benson, C ;
King, KR ;
Murphy, RL ;
Brun, SC .
AIDS, 2004, 18 (05) :775-779
[5]   First Case of 2019 Novel Coronavirus in the United States [J].
Holshue, Michelle L. ;
DeBolt, Chas ;
Lindquist, Scott ;
Lofy, Kathy H. ;
Wiesman, John ;
Bruce, Hollianne ;
Spitters, Christopher ;
Ericson, Keith ;
Wilkerson, Sara ;
Tural, Ahmet ;
Diaz, George ;
Cohn, Amanda ;
Fox, LeAnne ;
Patel, Anita ;
Gerber, Susan I. ;
Kim, Lindsay ;
Tong, Suxiang ;
Lu, Xiaoyan ;
Lindstrom, Steve ;
Pallansch, Mark A. ;
Weldon, William C. ;
Biggs, Holly M. ;
Uyeki, Timothy M. ;
Pillai, Satish K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (10) :929-936
[6]   Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China (vol 395, pg 497, 2020) [J].
Huang, C. ;
Wang, Y. ;
Li, X. .
LANCET, 2020, 395 (10223) :496-496
[7]   Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome [J].
Kim, Uh Jin ;
Won, Eun-Jeong ;
Kee, Seung-Jung ;
Jung, Sook-In ;
Jang, Hee-Chang .
ANTIVIRAL THERAPY, 2016, 21 (05) :455-459
[8]   A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [J].
Momattin, Hisham ;
Al-Ali, Anfal Y. ;
Al-Tawfiq, Jaffar A. .
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2019, 30 :9-18
[9]  
National Health Commission of the People's Republic of China, DIAGN TREATM NOV COR
[10]   Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020 [J].
Reusken, Chantal B. E. M. ;
Broberg, Eeva K. ;
Haagmans, Bart ;
Meijer, Adam ;
Corman, Victor M. ;
Papa, Anna ;
Charrel, Remi ;
Drosten, Christian ;
Koopmans, Marion ;
Leitmeyer, Katrin .
EUROSURVEILLANCE, 2020, 25 (06) :7-12